Presentation is loading. Please wait.

Presentation is loading. Please wait.

Ongoing and planned studies at ClinTRID

Similar presentations


Presentation on theme: "Ongoing and planned studies at ClinTRID"— Presentation transcript:

1 Ongoing and planned studies at ClinTRID
Project Funding Description (number of subjects) Main investigator, Coordinator, Key persons, Contact Status Initiated Expected to be completed 1. NORD-STAR Swedish Medical Research SLL Medication provided by BMS and UCB Pharma Unrestricted funds Nordic randomized clinical trial in early RA. Initial 4-way randomization (conventional vs. 3 biologics); re-randomization for patients in remission to immediate vs. delayed step-down therapy. Appr. 3 year duration per patient (800 patients) Ronald van Vollenhoven, Maria Seddighzadeh, Camilla Gustafsson, Eleonore Nilsson, Peter Westerling, Melinda Mild, Nancy Vivar First patient in IV/2012 2010 2017 2. IRBIS-retrospective International registry (>400) Ronald van Vollenhoven, Melinda Mild, Anna Andersson, Retrospectively >400 patients have been registered; manuscript in preparation 2020 3. IRBIS-prospective GSK International prospective registry (Projected:2000) Ronald van Vollenhoven, Melinda Mild, Anna Andersson, Noémi Györi, Sara Linder The prospective registry was opened on March 10, 2012; 52 patients included 2012 2025 4. CERERRA European registry collaboration (>3000) Katerina Chatzidionysiou Data on ca 3000 rituximab treated patients has been processed, 3 published articles, >6 presentations at EULAR and ACR 2009 2019 5. RING trial (rituximab in SLE) European randomized clinical trial with rituximab in refractory SLE nephritis (200) Ronald van Vollenhoven, Fred Houssiau, Peter Westerling, Adrian Levitsky, Noémi Györi In preparation 2018 6. Rituxilup ARUK in new-onset SLE nephritis (200) Ronald van Vollenhoven, Liz Lightstone, Peter Westerling, Adrian Levitsky, 7. TREES (anti-CD20 in SLE) European randomized clinical trial with anti-CD20 in non-renal SLE (200) Ronald van Vollenhoven, Ian Bruce, Peter Westerling, Adrian Levitsky 8. ULTRASOUND: Evaluation of diagnostic utility according to Bayes Swedish Collaboration Project (100) Hamed Rezaei, Yogan Kisten, Noémi Györi Ca 80 of 100 patients included; Poster EULAR 2013 2013 9. MUSCARA: Ultrasound support in choice of therapy Abbott Prospective Swedish collaborative project (120) Hamed Rezaei, Peter Westerling, Erik af Klint, Yogan Kisten, Noémi Györi First patient in study February 2013 2015 10. RHEUMASCAN: (fluorescence optical imaging) Feasibility study of new diagnostic tool Erik af Klint, Yogan Kisten, Noémi Györi, Anna Karlsson, Carolina Romanus 2014 11. SWEFOT 5-year follow-up 5-year clinical, radiological, and health-economic evaluation Ronald van Vollenhoven, Melinda Mild, Jonas Ericsson, Martin Neovius, Margareta Lindmark, Heather Miller, Adrian Levitsky, Noémi Györi, Nancy Vivar 12. SWEFOT Biomarkers Biomarkers in early RA, in collaboration with Crescendo (487) Karen Hambardzumyan, Melinda Mild, Adrian Levitsky, Nancy Vivar Two poster presentations at EULAR 2013 2011 13. SWEFOT PAMERA International GWAS collaboration through Mayo Clinic Ronald van Vollenhoven, Melinda Mild, Karen Hambardzumyan, Saedis Saevarsdottir, Leonid Padyukov DNA sent to Mayo Clinic, analyses in progress 14. SWEFOT POPERA Predictive x-ray progression in early RA Ronald van Vollenhoven, Melinda Mild, Adrian Levitsky Poster at EULAR 2013 15. SWEFOT Adipokines Adipokines in early RA, extension study Ronald van Vollenhoven, Kerstin Brismar, Melinda Mild, Adrian Levitsky, Karen Hambardzumyan, Anna Andersson, Inga-Lill Engvall, Nancy Vivar Adiponektin and leptin results available, IGF-1 pending. Analyses ongoing 16. SWEFOT ACPA fine specificity Study of ACPA fine specificity as prediction marker Saedis Saevarsdottir, Melinda Mild, Alf Kastbom, Anna Andersson, Adrian Levitsky Ongoing 17. SWEFOT Survivin Collaboration with Prof. Maria Bokarewa (Göteborg) Ronald van Vollenhoven, Maria Bokarewa, Melinda Mild, Karen Hambardzumyan, Adrian Levitsky Samples sent to Göteborg 18. CELLCEPT in SLE and vasculitis Clinical chart review project (180) Cecilia Lourdudoss, Sanaa Jamil Completed Presented at CORA 2013; manuscript in preparation 19. HCQ compliance International study (300) External, Cecilia Lourdudoss, Noémi Györi Enrollment to start during spring of 2013 20. Nutrition and therapy results in RA and SLE Registry study; PhD project (2000) Cecilia Lourdudoss 21. ADMIRE Clinical Trial (32) Ronald van Vollenhoven, Katerina Chatzidionysiou, Eleonore Nilsson Trial completed Results presented at ACR 2012; manuscript in preparation 2008 22. DOSERA Pfizer Clinical Trial (90) Ronald van Vollenhoven, Lara Dani, Seija Johansson Results presented at ACR2012; manuscript in preparation 23. ARTIS CZP UCB Pharma Certolizumab in RA, ARTIS registry study (400) Katerina.Chatzidionysiou Abstract EULAR 2012, Manuscript in preparation 24. ARTIS Treatment sequences Treatment sequences with biologic drugs in RA (~2000) First data at ACR 2011 25. TOCERRA Roche European registries collaboration (2000) Katerina Chatzidionysiou, Cem Gabay 2022 26. Review health-economic registry studies in Nordic countries Literature review; PhD project Heather Miller 27. Health-economic studies of data from SWEFOT, DOSERA and other trials Health-economic data analysis and modeling; PhD project Planning stage 28. Ultrasound in Psoriasis Pilot study Ronald van Vollenhoven, Mona Ståhle, Yogan Kisten, Hamed Rezaei, Noémi Györi 29. Request study Survey of infliximab treated patients Sanaa Jamil, Jenny Riazzoli Study completed . Analyses ongoing 30. Rituximab long-term follow up Follow-up of rituximab treated patients with SLE Sara Linder, Iva Gunnarsson, Noémi Györi 31. Rituximab B-cell markers Sara Linder, Noémi Györi, Vivi Malmström, Louise Berg 32. PDA study Study of PDA use in adalimumab treated patients Ronald van Vollenhoven Study completed. Some analyses and publication remaining.


Download ppt "Ongoing and planned studies at ClinTRID"

Similar presentations


Ads by Google